The role of gemtuzumab ozogamicin in combination chemotherapy regimens for primary resistant or relapsed acute myeloid leukemia Hien K. DuongMatt Kalaycio Clinical Trials Report 22 March 2009 Pages: 55 - 56
Predicting the response of CML patients to tyrosine kinase inhibitor therapy Deborah L. WhiteTimothy P. Hughes OriginalPaper 22 March 2009 Pages: 59 - 65
Chronic myelogenous leukemia stem cells: What’s new? Mhairi Copland OriginalPaper 22 March 2009 Pages: 66 - 73
Clinical implications of c-Kit mutations in acute myelogenous leukemia Muriel MalaiseDaniel SteinbachSelim Corbacioglu OriginalPaper 22 March 2009 Pages: 77 - 82
MicroRNA expression in acute myeloid leukemia Guido MarcucciMichael D. RadmacherClara D. Bloomfield OriginalPaper 22 March 2009 Pages: 83 - 88
Treatment of immunoglobulin light chain amyloidosis Morie A. GertzSteven R. Zeldenrust OriginalPaper 22 March 2009 Pages: 91 - 98
Treatment of relapsed and refractory myeloma Jonathan KaufmanCharise GleasonSagar Lonial OriginalPaper 22 March 2009 Pages: 99 - 107
The role of bisphosphonates in multiple myeloma Jessica LevyG. David Roodman OriginalPaper 22 March 2009 Pages: 108 - 112